SLAS Discovery Volume 39 debuts AI-powered workflows and massive proteome datasets to accelerate drug development

New research from SLAS Discovery introduces the Binder2030 dataset and label-free AI imaging to accelerate cancer and parasitic disease drug development.

By: AXL Media

Published: Apr 30, 2026, 9:22 AM EDT

Source: Information for this report was sourced from EurekAlert!

Next-Generation Tools for Challenging Targets

The Society for Laboratory Automation and Screening (SLAS) has released Volume 39 of its flagship journal, SLAS Discovery, featuring research aimed at modernizing the drug discovery pipeline. The new volume focuses on four primary areas: AI-assisted live-cell imaging, covalent fragment identification, parasitic disease assays, and large-scale proteome datasets. By integrating artificial intelligence and mass spectrometry, these studies address the logistical bottlenecks that often slow the transition from laboratory research to clinical application, particularly for complex diseases like cancer and Chagas disease.

AI-Driven Live-Cell Imaging Without Labels

A major highlight of the volume is a novel AI-powered workflow designed to analyze T-cell mediated tumor killing. Traditionally, these assays require fluorescent dyes or nuclear labels to track immune cell activity, which can introduce phototoxicity and experimental artifacts. The new brightfield microscopy analysis eliminates the need for these labels, offering a "hands-free" approach that simplifies the workflow while maintaining high consistency. This advancement allows researchers to observe functional activity in immune cell therapeutics more naturally, reducing the risk of segmentation errors and improving the robustness of hit calling in cancer immunotherapy research.

Tackling the MPP8 Protein and Chagas Disease

The volume also reports on specific screening successes for historically difficult targets. Using high-throughput MALDI-TOF mass spectrometry, researchers identified two novel covalent fragments that target the MPP8 protein, a methyl-lysine reader with significant implications for cancer treatment. Simultaneously, another study validated a 384-well high-content imaging assay to combat Trypanosoma cruzi, the parasite responsible for Chagas disease. This multiplexed platform is particularly valuable as it measures both anti-parasitic efficacy and host cell toxicity, providing a safer alternative to the side-effect-prone treatments currently available.